Ritonavir

Active ingredient: Ritonavir

In short: Ritonavir tablets are indicated in combination with other antiretroviral agents for the treatment of HIV-1 infection.

Forms & strengthsRitonavir tablets USP, 100 mg are white to off-white, film-coated, ovaloid tablets, debossed with ‘Z’ on one side and ‘24’ on other side.
LabelAurobindo Pharma Limited
Label updatedSep 24, 2026

What is Ritonavir used for?

Ritonavir tablets are indicated in combination with other antiretroviral agents for the treatment of HIV-1 infection.

âš  Boxed warning (FDA's strongest warning)

Co-administration of ritonavir with several classes of drugs including sedative hypnotics, antiarrhythmics, or ergot alkaloid preparations may result in potentially serious and/or life-threatening adverse events due to possible effects of ritonavir on the hepatic metabolism of certain drugs. Review medications taken by patients prior to prescribing ritonavir or when prescribing other medications to patients already taking ritonavir .

Ritonavir dosage

Ritonavir tablets must be used in combination with other antiretroviral agents.

Administer ritonavir tablets orally. Swallow ritonavir tablets whole. Do not chew, break or crush ritonavir tablets. Take ritonavir tablets with meals.

Recommended Dosage for Treatment of HIV-1:

The recommended dosage of ritonavir is 600 mg twice daily by mouth to be taken with meals. Use of a dose titration schedule may help to reduce treatment-emergent adverse events while maintaining appropriate ritonavir plasma levels. Start ritonavir tablets at no less than 300 mg twice daily and increase at 2 to 3 day intervals by 100 mg twice daily. Do not exceed the maximum dose of 600 mg twice daily upon completion of the titration .

Ritonavir tablets must be used in combination with other antiretroviral agents . The recommended dosage of ritonavir tablets in pediatric patients older than 1 month is 350 to 400 mg per m2 twice daily by mouth to be taken with meals. Do not exceed 600 mg twice daily. Start ritonavir tablets at 250 mg per m2 twice daily and increase at 2 to 3 day intervals by 50 mg per m2 twice daily. If patients do not tolerate 400 mg per m2 twice daily due to adverse events, use the highest tolerated dose for maintenance therapy in combination with other antiretroviral agents, or consider using alternative therapy .

Reduce dose of ritonavir tablet when used with other protease inhibitors: atazanavir, darunavir, fosamprenavir, saquinavir, and tipranavir.

Consult the full prescribing information and clinical study information of these protease inhibitors when they are co-administered with a reduced dose of ritonavir .

How to take Ritonavir — instructions & advice from the label

Advise the patient to read the FDA-approved patient labeling (Patient Information)

General Administration Information

:

Advise patients and caregivers to pay special attention to accurate preparation and administration of their dose to minimize the risk of accidental overdose or underdose of ritonavir tablets.

Advise caregivers to inform their healthcare provider if their child’s weight changes in order to make sure that the child’s ritonavir tablets dose is adjusted as needed.

Advise patients to take ritonavir tablets with meals.

For adult patients taking ritonavir tablets, the maximum dose of 600 mg twice daily by mouth with meals should not be exceeded.

Advise patients to remain under the care of a physician while using ritonavir tablets and to take ritonavir tablets and other concomitant antiretroviral therapy every day as prescribed. Ritonavir tablets must always be used in combination with other antiretroviral drugs. Advise patients not to alter the dose or discontinue therapy without consulting with their healthcare provider. If a dose of ritonavir tablet is missed patients should take the dose as soon as possible and then return to their normal schedule. …

Warnings & precautions

Do not take this medicine if: Consult the prescribing information of the co-administered protease inhibitor for contraindication information for that product.

Ritonavir tablets are contraindicated in patients with known hypersensitivity (e.g., toxic epidermal necrolysis (TEN) or Stevens-Johnson syndrome) to ritonavir or any of its ingredients.

Ritonavir tablets are contraindicated with drugs that are highly dependent on CYP3A for clearance and for which elevated plasma concentrations are associated with serious and/or life-threatening reactions .

Alpha 1- Adrenoreceptor Antagonist: alfuzosin

Antianginal: ranolazine

Antiarrhythmics: amiodarone, dronedarone, flecainide, propafenone, quinidine

Antifungal: voriconazole

Anti-gout: colchicine

Antipsychotics: lurasidone, pimozide

Ergot Derivatives: dihydroergotamine, ergotamine, methylergonovine

GI Motility Agent: cisapride

HMG-CoA Reductase Inhibitors: lovastatin, simvastatin

Microsomal triglyceride transfer protein (MTTP) Inhibitor: lomitapide

Non-opioid Analgesic (selective blocker of Nav1.8 sodium channels): suzetrigine

PDE5 Inhibitor: sildenafil (Revatio®) when used for the treatment of pulmonary arterial hypertension

Sedative/Hypnotics: triazolam, orally administered midazolam

Ritonavir tablets are contraindicated with drugs that are potent CYP3A inducers where significantly reduced ritonavir plasma concentrations may be associated with the potential for loss of virologic response and possible resistance and cross-resistance .

Anticancer Agents: apalutamide

Herbal Products: St. John's Wort (hypericum perforatum)

Initiation of ritonavir, a CYP3A inhibitor, in patients receiving medications metabolized by CYP3A or initiation of medications metabolized by CYP3A in patients already receiving ritonavir, may increase plasma concentrations of medications metabolized by CYP3A. …

Ritonavir side effects

The following adverse reactions are discussed in greater detail in other sections of the labeling.

Drug Interactions

Hepatotoxicity

Pancreatitis

Allergic Reactions/Hypersensitivity

When co-administering ritonavir with other protease inhibitors, see the full prescribing information for that protease inhibitor including adverse reactions.

Because clinical trials are conducted under widely varying conditions, adverse reactions rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.

Adverse Reactions in Adults

The safety of ritonavir alone and in combination with other antiretroviral agents was studied in 1,755 adult patients. Table 1 lists treatment-emergent Adverse Reactions (with possible or probable relationship to study drug) occurring in greater than or equal to 1% of adult patients receiving ritonavir in combined Phase II/IV studies.

The most frequently reported adverse drug reactions among patients receiving ritonavir alone or in combination with other antiretroviral drugs were gastrointestinal (including diarrhea, nausea, vomiting, abdominal pain (upper and lower)), neurological disturbances (including paresthesia and oral paresthesia), rash, and fatigue/asthenia. …

Drug interactions

When co-administering ritonavir with other protease inhibitors (atazanavir, darunavir, fosamprenavir, saquinavir, and tipranavir), see the full prescribing information for that protease inhibitor including important information for drug interactions.

Ritonavir is an inhibitor of cytochrome P450 3A (CYP3A) and may increase plasma concentrations of agents that are primarily metabolized by CYP3A. Agents that are extensively metabolized by CYP3A and have high first pass metabolism appear to be the most susceptible to large increases in AUC (greater than 3-fold) when co-administered with ritonavir. Thus, co-administration of ritonavir with drugs highly dependent on CYP3A for clearance and for which elevated plasma concentrations are associated with serious and/or life-threatening events is contraindicated. Co-administration with other CYP3A substrates may require a dose adjustment or additional monitoring as shown in Table 3.

Ritonavir also inhibits CYP2D6 to a lesser extent. Co-administration of substrates of CYP2D6 with ritonavir could result in increases (up to 2-fold) in the AUC of the other agent, possibly requiring a proportional dosage reduction. …

About this medicine

Ritonavir is an inhibitor of HIV protease with activity against the Human Immunodeficiency Virus (HIV).

Ritonavir is chemically designated as 10-Hydroxy-2-methyl-5-(1-methylethyl)-1-[2-(1­-methylethyl)-4-thiazolyl]-3,6-dioxo-8,11-bis(phenylmethyl)-2,4,7,12-tetraazatridecan-13-oic acid, 5-thiazolylmethyl ester, [5S-(5R*,8R*,10R*,11R*)]. Its molecular formula is C37H48N6O5S2, and its molecular weight is 720.95. Ritonavir has the following structural formula:

Ritonavir USP is a white to light-tan, crystalline powder. Ritonavir has a bitter metallic taste. It is freely soluble in methanol and ethanol, soluble in isopropanol and practically insoluble in water. …

Disclaimer: This page is for general information only and is not medical advice. It is a condensed summary of the official FDA-approved label — it does not replace the full prescribing information or the advice of your doctor or pharmacist. Always follow your prescriber's instructions and read the medication guide that comes with your medicine.

Source: FDA-approved label via DailyMed (U.S. National Library of Medicine), label set ID 11f757f1-cf48-47a8-925e-918359cbd2d4. Read the full official label on DailyMed.

Related medicines

Amoxicillin Azithromycin Doxycycline Amoxicillin and Clavulanate Cephalexin Valacyclovir Sulfamethoxazole and Trimethoprim Nitrofurantoin